GlassScriptPhysician profile
Cameron Todd King
NPI 1457338436
$2,678.05
in general payments reported to CMS, 2019-2025
40 companies · $614 in 2025
The $614 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $107 · 2021: $21.25 · 2022: $359 · 2023: $391 · 2024: $676 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $341.20 | 2019-2025 | Proclaim, Freestyle Libre 3, Eterna |
| Cranial Technologies, INC | $176.05 | 2019-2025 | Doc Band |
| Exact Sciences Corporation | $144.89 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $135.51 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $131.65 | 2019-2025 | Farxiga, Flumist Quadrivalent, Airsupra |
| Corium, LLC | $108.48 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $107.79 | 2024-2025 | Qelbree |
| Hologic Sales and Service, LLC | $106.18 | 2019-2024 | Aptima |
| Merck Sharp & Dohme LLC | $105.92 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Teleflex LLC | $104.99 | 2024 | Urolift |
| Novo Nordisk INC | $87.79 | 2022-2025 | Ozempic, Rybelsus |
| Sanofi Pasteur INC. | $86.19 | 2019-2022 | |
| Alk-Abello, INC | $83.90 | 2025 | Neffy |
| Globus Medical, INC. | $74.38 | 2025 | Senza |
| Glaxosmithkline, LLC. | $73.07 | 2019-2023 | Shingrix, Bexsero, Arexvy |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $72.02 | 2023 | Inspire |
| Genentech USA, INC. | $66.64 | 2019 | |
| Lilly USA, LLC | $65.19 | 2022-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $57.13 | 2022-2024 | |
| Nevro Corp. | $44.36 | 2022-2024 | Senza |
| Ironshore Pharmaceuticals INC. | $41.33 | 2019-2020 | |
| Dynavax Technologies Corporation | $41.13 | 2023 | Heplisav-B |
| Dexcom, INC. | $40.63 | 2024 | Dexcom G6 Transmitter |
| Tris Pharma INC | $38.44 | 2020-2025 | Dyanavel Xr |
| Bayer Healthcare Pharmaceuticals INC. | $35.67 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.60 | 2019-2021 | |
| Abbvie INC. | $31.70 | 2024 | |
| Adlon Therapeutics L.P. | $30.85 | 2019-2020 | |
| Allergan, INC. | $24.64 | 2019 | |
| Srs Medical Systems, INC. | $24.04 | 2024 | Urocuff-Dc Disposable, Single, Ct3000 Pro Base Unit |
| Photonicare INC | $21.95 | 2023 | Otosight Middle Ear Scope |
| Vertiflex, INC. | $18.95 | 2019 | |
| Verrica Pharmaceuticals INC. | $18.01 | 2024 | Ycanth |
| Vbi Vaccine (Delaware) INC. | $17.21 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.75 | 2024 | |
| Collegium Pharmaceutical, INC. | $14.70 | 2025 | Jornay Pm |
| Shire North American Group INC | $14.63 | 2019 | |
| Tms Neurohealth Centers INC. | $13.53 | 2025 | Tms Neurohealth Centers INC. |
| Seqirus USA INC | $13.04 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.